1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
[2]
2. Zheng R, Zeng H, Zuo T, et al. Lung cancer incidence and mortality in China, 2011. Thoracic cancer, 2016, 7(1): 94-99.
[3]
3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
[4]
4. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin roentgenol, 2005, 40(2): 90-97.
[5]
5. Butt YM, Allen TC. Yasmeen The demise of the term bronchioloalveolar carcinoma. Arch Pathol Lab Med, 2015, 139(8): 981-983.
[6]
6. Zell JA, Ou SH, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol, 2005, 23(33): 8396-8405.
[7]
7. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc, 2011, 8(5): 381-385.
[8]
8. Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol, 2016, 11(5): 666-680.
[9]
9. Raz DJ, Jablons DM. Bronchioloalveolar carcinoma is not associated with younger age at diagnosis: an analysis of the SEER database. J Thorac Oncol, 2006, 1(4): 339-343.
[10]
10. Kim HY, Shim YM, Lee KS, et al. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology, 2007, 245(1): 267-275.
[11]
11. Hjelmborg J, Korhonen T, Holst K, et al. Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer. Thorax, 2017, 72(11): 1021-1027.
[12]
12. Lopez Encuentra A, Pozo Rodriguez F, Martin de Nicolas JL, et al. Bronchioloalveolar carcinoma in Spain: a rare and different form of lung cancer. Arch bronconeumol, 2006, 42(8): 399-403.
[13]
13. Camus M, Siemiatycki J, Meek B. Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. N Engl J Med, 1998, 338(22): 1565-1571.
[14]
14. Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ, 2005, 330(7485): 223.
[15]
15. Barone-Adesi F, Chapman RS, Silverman DT, et al. Risk of lung cancer associated with domestic use of coal in Xuanwei, China: retrospective cohort study. BMJ, 2012, 345: e5414.
[16]
16. Kurmi OP, Arya PH, Lam KB, et al. Lung cancer risk and solid fuel smoke exposure: a systematic review and meta-analysis. Eur Respir J, 2012, 40(5): 1228-1237.
[17]
17. Barcenas CH, Delclos GL, El-Zein R, et al. Wood dust exposure and the association with lung cancer risk. Am J Ind Med, 2005, 47(4): 349-357.
[18]
18. Arrieta O, Martinez-Barrera L, Trevino S, et al. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J Thorac Oncol, 2008, 3(8): 887-893.
[19]
19. Bode AM, Dong Z, Wang H. Cancer prevention and control: alarming challenges in China. Nati Sci Rev, 2016, 3(1): 117-127.
[20]
20. Jia PL, Zhang C, Yu JJ, et al. The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies. J Cancer Res Clin Oncol, 2018, 144(2): 229-240.
[21]
21. Yang Y, Fujita J, Tokuda M, et al. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int, 2001, 21(3): 106-111.
[22]
22. Hopkins RJ, Duan F, Chiles C, et al. Reduced expiratory flow rate among heavy smokers increases lung cancer risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort. Ann Am Thorac Soc, 2017, 14(3): 392-402.
[23]
23. Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep, 2002, 4(5): 415-426.
[24]
24. Rodriguez-Lara V, Hernandez-Martinez JM, Arrieta O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J Thorac Dis, 2018, 10(1): 482-497.
[25]
25. Cheng TD, Darke AK, Redman MW, et al. Smoking, sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue. J Natl Cancer Inst, 2018, 110(7): 734-742.
[26]
26. Wislez M, Massiani MA, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest, 2003, 123(6): 1868-1877.
[27]
27. Popat N, Raghavan N, Mclvor RA. Severe bronchorrhea in a patient with bronchioloalveolar carcinoma. Chest, 2012, 141(2): 513-514.
[28]
28. Remi C, Remi J, Bausewein C. Pharmacological management of bronchorrhea in malignant disease: a systematic literature review. J Pain Symptom Manage, 2016, 51(5): 916-925.
[29]
29. Inamura K. Clinicopathological characteristics and mutations driving development of early lung adenocarcinoma: tumor initiation and progression. Int J Mol Sci, 2018, 19(4): 1259-1264.
31. Cha YJ, Shim HS. Biology of invasive mucinous adenocarcinoma of the lung. Transl Lung Cancer Res, 2017, 6(5): 508-512.
[32]
32. Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: the case for two diseases. Clin lung cancer, 2008, 9(1): 24-29.
[33]
33. Raptis CA, Robb CL, Bhalla S. Tumor Staging of Lung Cancer: Essential Concepts for the Radiologist. Radiol Clin North Am, 2018, 56(3): 391-398.
[34]
34. Jung JI, Kim H, Park SH, et al. CT differentiation of pneumonic-type bronchioloalveolar cell carcinoma and infectious pneumonia. Br J Radiol, 2001, 74(882): 490-494.
[35]
35. Zwirewich CV, Miller RR, Muller NL. Multicentric adenocarcinoma of the lung: CT-pathologic correlation. Radiology, 1990, 176(1): 185-190.
[36]
36. Liu YY, Chen YM, Huang MH, et al. Prognosis and recurrent patterns in bronchioloalveolar carcinoma. Chest, 2000, 118(4): 940-947.
[37]
37. Ambrosini V, Nicolini S, Caroli P, et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol, 2012, 81(5): 988-1001.
[38]
38. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. Chest, 2017, 151(1): 193-203.
[39]
39. Breathnach OS, Ishibe N, Williams J, et al. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer, 1999, 86(7): 1165-1173.
[40]
40. Cabanero M, Tsao MS. Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer. Curr Oncol, 2018, 25(S1): 38-44.
[41]
41. Raz DJ, Kim JY, Jablons DM. Diagnosis and treatment of bronchioloalveolar carcinoma. Curr Opin Pulm Med, 2007, 13(4): 290-296.
[42]
42. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg, 2002, 74(5): 1640-1647.
[43]
43. Whitson BA, Groth SS, Andrade RS, et al. Invasive adenocarcinoma with bronchoalveolar features: a population-based evaluation of the extent of resection in bronchoalveolar cell carcinoma. J Thorac Cardiovasc Surg, 2012, 143(3): 591-600.
[44]
44. Ahmad U, Wang Z, Bryant AS, et al. Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry. Ann Thorac Surg, 2012, 94(3): 935-941.
[45]
45. Scagliotti GV, Smit E, Bosquee L, et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung cancer, 2005, 50(1): 91-96.
[46]
46. Lau DH, Moon J, Davies AM, et al. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin lung cancer, 2013, 14(4): 351-355.
[47]
47. Yamakawa H, Takayanagi N, Ishiguro T, et al. A favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma. Intern Med, 2013, 52(24): 2781-2784.
49. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchiolo -alveolar features. J Mol Diagn, 2007, 9(3): 320-326.
[50]
50. Zell JA, Ou SH, Ziogas A, et al. Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol, 2006, 17(8): 1255-1262.
[51]
51. Casali C, Rossi G, Marchioni A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol, 2010, 5(6): 830-836.
